1-3 of 3
Tim Beißbarth
Close
Sort by
Journal Articles

An Evidence Based Reporting System for Molecular Tumorboards Identifies Novel Therapeutics for T-Cell Lymphomas

Nicole Schmidt, Kevin Kornrumpf, Lena Ries, Bjoern Chapuy, Charlotte Höltermann, Tim Beißbarth, Jürgen Dönitz, Raphael Koch
Journal: Blood
Blood (2022) 140 (Supplement 1): 11896–11897.
https://doi.org/10.1182/blood-2022-167435
Published: 2022
Journal Articles

Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling By Suppression of Mir-146a in Acute Myeloid Leukemia

Sebastian Mohr, Carmen Doebele, PhD, Tobias Berg, MD, Federico Comoglio, PhD, Julia Beck, PhD, Gabriela Alexe, PhD, Jasmin Corso, Hanibal Bohnenberger, MD, Philipp Stroebel, MD, Astrid Wachter, Tim Beissbarth, PhD, Frank Schnuetgen, PhD, Nadine Haetscher, PhD, Stefanie Goellner, PhD, Arefeh Rouhi, PhD, Lars Palmqvist, MD PhD, Michael A Rieger, PhD, Carsten Mueller-Tidow, MD, Florian Kuchenbauer, Ekkehardt Schuetz, MD, Henning Urlaub, PhD, Kimberly Stegmaier, MD, R. Keith Humphries, MD PhD, Hubert Serve, MD, Thomas Oellerich, MD
Journal: Blood
Blood (2016) 128 (22): 1533.
https://doi.org/10.1182/blood.V128.22.1533.1533
Published: 2016
Journal Articles

Deciphering The Molecular Impact Of Myc Overexpression On B Cell Receptor Signaling and Its Implications For Burkitt Lymphoma Treatment

Thomas Oellerich, Jasmin Corso, Simone Lemeer, Ekkehard Schütz, Julia Beck, Stephan Lorenzen, Tim Beissbarth, Silvia Münch, Pascal Degenhardt, Michael Engelke, Christoph Lenz, Bernhard Küster, Henning Urlaub, Hubert Serve, MD
Journal: Blood
Blood (2013) 122 (21): 3018.
https://doi.org/10.1182/blood.V122.21.3018.3018
Published: 2013